drugset
drugset / Trial / NCT05189548

To Evaluate the Safety and Primary Immunogenicity of Cell-free (Three-component) Combination Vaccine for Phase I Immunogenicity in Children and Infants

NCT05189548 ↗

Phase 1/2 Unknown 72 enrolled Changchun BCHT Biotechnology Co.
NaSingle-groupOpen-labelPrevention

Summary

A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine.Main purpose: To evaluate the safety of the adsorbed cell-free whitening break (three components) combination vaccine;Secondary purpose: To preliminarily evaluate the immunogenicity of the adsorbed cell-free whitening break (three components) combination vaccine.

Timeline

Start
2021-12-10
Primary completion
2022-04-30
Completion
2022-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Adsorbed cell-free leukiche (three-component) combination vaccine Vaccine — —

Indications

No indication recorded.